


DECISION DIAGNOSTICS,



OTCPINK: DECN

DECN Family of Products

- GenUltimate®
- GenPrecis®
- GenSure®
- GenAccord®
- Alltara®
- GenChoice®

Diabetic Test Strip Market

- \$10 Billion Annual Sales, Worldwide - 4-7% annual growth
- Estimates as high as \$15 Billion by 2022
- J&J Lifescan's Ultra Strips
- \$3 Billion Revenue getting squeezed by MediCare
- 5 Million Customer Base - Loyal to Their Meters
- Major Players Fail to Launch New Products in Last 6 years, J&J recalls 2 million Meters in
- Other Major Players: Roche, Abbott and Bayer

STATS

Current Stock Price .05

52 Week High 0.17

52 Week Low 0.03

Shares Outstanding 25.16M

Float 21.01M

Investing Highlights

Decision Diagnostics Corp. is a worldwide regulated OTC diagnostics and home testing products manufacturer and distributor. We manufacture in Pennsylvania and Seoul, South Korea and then market the U.S. and other International markets.

Our U.S. FDA approved GenUltimate and GenSure Blood Glucose Test Strip for diabetics, the first alternative technology glucose testing strips for diabetics that has been launched since 1998, and the first alternative technology test strip product sold into the U.S. market since early 2008, GenUltimate and GenSure both make use of the worldwide popularity of the Johnson and Johnson family of Glucometers.

In 2018 and early 2019, DECN will launch to the domestic and International markets three additional test strips, its GenChoice, GenAccord and GenCambre test strips. DECN will also launch its GenPrecis Precise glucometer and test strip system offering diabetics near hospital level precision in a hand held at-home testing system.

Key Patent Litigation Events

- Aug 2013 USPTO Rules J&J Main Patent Is Invalid
- Oct 2013 - Permanent Stay Granted
- Nov 2013 - Appellate Court Reverses Injunction Invalidates All System Patents (principal of exhaustion)
- 30 months later all patent infringement cases settled, DECN and PharmaTech victorious
- May 2016 – J&J Settles Case with DECN paying to DECN a confidential settlement amount and granting to Float 21.01M certain patent licenses. Value of the settlement is 7 figures.
- In March 2016 DECN/ PharmaTech file \$400 million patent infringement suit against J&J
- In September 2017 DECN amends its suit to allege patent infringement under Doctrine of Equivalents and proves up damages in the range of \$400 - \$700 million.
- In January 2018 J&J announces discussions with Sinocare in effort to sell its diabetes divisions



Our PharmaTech Solutions subsidiary is the manufacturer and design specifier (design engineer) of our technologies. We sell into a U.S. market estimated to be \$5.4 billion in 2018 and into a worldwide market expected to be \$14.68 billion in 2022.

We are manufacturers of a line of FDA-cleared, cost effective glucose test strips. We aim to lessen the financial burden of home glucose testing. We also provide a range of wholesale prescription drugs and home diagnostic and treatment products.

We manufacture the GenStrip50 and GenUltimate! Glucose test strips for use with the LifeScan's Onetouch® Ultra®, Ultra®2, and UltraMini® meters. These FDA cleared test strips provide high quality performance and familiar ease of use at a fraction of the cost of the brand name alternative. We also provide wholesale prescription drug and treatment products often needed for diabetes and elderly patients.

COMPETITIVE ADVANTAGE

Product: GenUltimate! Blood Glucose Test Strip

PharmaTech Solutions Glucose Test Strip

FDA cleared for use with OneTouch® Ultra®, Ultra®2, and UltraMini® Meters

Available in GenUltimate! brand or in private label.

PharmaTech Solutions is a wholly owned subsidiary of Decision Diagnostics Corp. (OTCBB:DECN)

Types of Products: Home diagnostic and testing supplies

Primary Customer: Owners of LifeScan® OneTouch® Ultra®, Ultra®2, and UltraMini® devices

Typical Usage: 3-8 strips daily

An estimated 29.1 million people in the US are living with diabetes

The population of people living with diabetes is on the rise – approximately 9 million are unaware they have the disease

An estimated 86 million Americans are considered to have prediabetes

GenUltimate! works with the world's most popular meter

Users do not have to switch to a new meter

Users enjoy the same small sample size and same fast results they are already accustomed to

GenUltimate! costs 80% less than the name brand test strips


Diabetics need to test frequently (3-8 times per day) to maintain a healthy lifestyle

There is an increasing demand for low-cost alternatives for over- priced testing supplies





DECISION DIAGNOSTICS, INC.



PRIVATE PLACEMENT UP TO \$2 MM

USE OF PROCEEDS

Capital	Investment	General	Sales	PharmaTech	FDA	General	Total
Infused	Plant & Equip	and Administrative	and Marketing	Technology Inv.	and Training Materials	Working Capital	Investment
	Allocation	Allocation	Allocation	Allocation	Allocation	Allocation	
100%	10%	10%	30%	5%	5%	40%	
500K	\$50,000	\$50,000	\$150,000	\$25,000	\$25,000	\$200,000	\$500,000
1000K	\$100,000	\$100,000	\$300,000	\$50,000	\$50,000	\$400,000	\$1,000,000
1500K	\$150,000	\$150,000	\$450,000	\$75,000	\$75,000	\$600,000	\$1,500,000
2000K	\$200,000	\$200,000	\$600,000	\$100,000	\$100,000	\$800,000	\$2,000,000
2500K	\$250,000	\$250,000	\$750,000	\$125,000	\$125,000	\$1,000,000	\$2,500,000

About PharmaTech Solutions, Inc. Board of Directors

Keith Berman, Chief Financial Officer, Secretary and Director

Specializing in healthcare software including intranet and Internet systems for the past 15 years and a founder of PharmaTech Solutions Corp., Keith Berman brings more than 22 years experience in the healthcare field, having worked with such companies as Technician Corporation and Boehringer-Mannheim Corporation. He is the founder of Medicius Inc., and served as that company's president at the time of its acquisition by instaCare Corp. Mr. Berman also was the founder of Cymedix, the operating division of Ramp Corp. (formerly Medix Resources) (AMEX: RCO), a public company. Mr. Berman received his B.A. and M.B.A. from Indiana University.

Robert Jagunich, Director

Robert Jagunich brings 27 years of experience in the medical systems and device industry. Since joining PharmaTech Solutions, Mr. Jagunich has also served president at New Abilities Systems, a privately held manufacturer of advanced electronic systems used in rehabilitation. From April 1996 through December 1997, he served as a director of Cymedix Corporation, the operating division of Ramp Corp. (AMEX: RCO). Mr. Jagunich also has provided consulting services to such clients as Johnson and Johnson.